vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Rumble Inc. (RUM). Click either name above to swap in a different company.
Rumble Inc. is the larger business by last-quarter revenue ($27.1M vs $18.7M, roughly 1.5× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -120.8%, a 120.0% gap on every dollar of revenue. On growth, Rumble Inc. posted the faster year-over-year revenue change (-10.5% vs -25.7%). CytomX Therapeutics, Inc. produced more free cash flow last quarter ($-15.8M vs $-31.7M). Over the past eight quarters, Rumble Inc.'s revenue compounded faster (15.2% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Rumble is a Canadian-American online video platform, web hosting, and cloud services business headquartered in Toronto, Canada, with its U.S. headquarters in Longboat Key, Florida. It was founded in 2013 by Chris Pavlovski, a Canadian technology entrepreneur. Rumble's cloud services business hosts Truth Social, and the video platform is popular among American conservative and far-right users. Rumble has been described as "alt-tech".
CTMX vs RUM — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $27.1M |
| Net Profit | $-154.0K | $-32.7M |
| Gross Margin | — | 5.5% |
| Operating Margin | -6.9% | -131.1% |
| Net Margin | -0.8% | -120.8% |
| Revenue YoY | -25.7% | -10.5% |
| Net Profit YoY | 97.6% | 86.2% |
| EPS (diluted) | — | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $27.1M | ||
| Q3 25 | — | $24.8M | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $50.9M | $23.7M | ||
| Q4 24 | $38.1M | $30.2M | ||
| Q3 24 | $33.4M | $25.1M | ||
| Q2 24 | $25.1M | $22.5M | ||
| Q1 24 | $41.5M | $17.7M |
| Q4 25 | — | $-32.7M | ||
| Q3 25 | — | $-16.3M | ||
| Q2 25 | $-154.0K | — | ||
| Q1 25 | $23.5M | $-2.7M | ||
| Q4 24 | $18.9M | $-236.8M | ||
| Q3 24 | $5.7M | $-31.5M | ||
| Q2 24 | $-6.5M | $-26.8M | ||
| Q1 24 | $13.8M | $-43.3M |
| Q4 25 | — | 5.5% | ||
| Q3 25 | — | -1.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -26.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | -45.4% | ||
| Q2 24 | — | -58.8% | ||
| Q1 24 | — | -79.5% |
| Q4 25 | — | -131.1% | ||
| Q3 25 | — | -113.6% | ||
| Q2 25 | -6.9% | — | ||
| Q1 25 | 44.4% | -153.5% | ||
| Q4 24 | 46.4% | -80.1% | ||
| Q3 24 | 12.3% | -131.0% | ||
| Q2 24 | -33.7% | -172.7% | ||
| Q1 24 | 28.1% | -197.4% |
| Q4 25 | — | -120.8% | ||
| Q3 25 | — | -65.7% | ||
| Q2 25 | -0.8% | — | ||
| Q1 25 | 46.2% | -11.2% | ||
| Q4 24 | 49.6% | -783.2% | ||
| Q3 24 | 17.2% | -125.9% | ||
| Q2 24 | -26.0% | -119.2% | ||
| Q1 24 | 33.3% | -244.1% |
| Q4 25 | — | $-0.13 | ||
| Q3 25 | — | $-0.06 | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-0.01 | ||
| Q4 24 | — | $-1.17 | ||
| Q3 24 | — | $-0.15 | ||
| Q2 24 | — | $-0.13 | ||
| Q1 24 | — | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $237.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $274.8M |
| Total Assets | $175.1M | $336.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $237.9M | ||
| Q3 25 | — | $269.8M | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | $301.3M | ||
| Q4 24 | $38.1M | $114.0M | ||
| Q3 24 | $40.6M | $132.0M | ||
| Q2 24 | $43.2M | $154.2M | ||
| Q1 24 | $36.2M | $183.8M |
| Q4 25 | — | $274.8M | ||
| Q3 25 | — | $302.2M | ||
| Q2 25 | $119.9M | — | ||
| Q1 25 | $25.0M | $339.6M | ||
| Q4 24 | $-456.0K | $-63.1M | ||
| Q3 24 | $-23.5M | $166.1M | ||
| Q2 24 | $-31.2M | $192.7M | ||
| Q1 24 | $-31.7M | $210.7M |
| Q4 25 | — | $336.8M | ||
| Q3 25 | — | $367.2M | ||
| Q2 25 | $175.1M | — | ||
| Q1 25 | $98.5M | $391.1M | ||
| Q4 24 | $120.5M | $195.3M | ||
| Q3 24 | $139.0M | $217.2M | ||
| Q2 24 | $159.2M | $243.2M | ||
| Q1 24 | $184.7M | $263.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $-29.4M |
| Free Cash FlowOCF − Capex | $-15.8M | $-31.7M |
| FCF MarginFCF / Revenue | -84.6% | -117.2% |
| Capex IntensityCapex / Revenue | 0.1% | 8.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $-70.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-29.4M | ||
| Q3 25 | — | $-10.6M | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.0M | $-14.5M | ||
| Q4 24 | $-19.9M | $-12.4M | ||
| Q3 24 | $-20.7M | $-19.1M | ||
| Q2 24 | $-19.5M | $-21.7M | ||
| Q1 24 | $-26.0M | $-33.9M |
| Q4 25 | — | $-31.7M | ||
| Q3 25 | — | $-12.0M | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | $-14.6M | ||
| Q4 24 | $-20.0M | $-12.4M | ||
| Q3 24 | $-20.7M | $-19.9M | ||
| Q2 24 | $-19.6M | $-23.1M | ||
| Q1 24 | $-26.2M | $-34.3M |
| Q4 25 | — | -117.2% | ||
| Q3 25 | — | -48.6% | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | -61.7% | ||
| Q4 24 | -52.5% | -40.9% | ||
| Q3 24 | -62.1% | -79.5% | ||
| Q2 24 | -78.2% | -102.8% | ||
| Q1 24 | -63.1% | -193.3% |
| Q4 25 | — | 8.5% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | 0.6% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.1% | 3.4% | ||
| Q2 24 | 0.4% | 6.1% | ||
| Q1 24 | 0.3% | 2.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
RUM
| Audience Monetization | $23.8M | 88% |
| Other Initiatives | $3.3M | 12% |
